Adam Zamecnik
Reporter
Adam has previously worked at GlobalData Media as a Healthcare Reporter, writing longer and shorter articles for the public website Pharmaceutical Technology and the Pharma Intelligence Centre. During his time there, Adam focused on topics such as cell and gene therapy, vaccine research, and new approaches to the treatment of haematological conditions. He has also covered the development of new biosimilars, the production of complex generics, and legal battles between Big Pharma. Prior to this, Adam wrote as a freelance reporter for the likes of Vice World News. Adam holds an MA in International Journalism from City, University of London.
Latest From Adam Zamecnik
Amneal Secures Fourth 505(b)(2) Injectable Approval Of 2024 With Bortezomib
Highlighting the company’s ongoing turn towards more complex products, Amneal has secured the fourth approval of a 505(b)(2) injectable product this year with the greenlighting of the anti-cancer agent bortezomib.
Hikma Launches Multiple Concentrations Of Clindamycin In The US
After presenting its interim results for the past six months in August, Hikma has announced a further injectable launch in the US while also dealing with legal developments in the country.
Apotex Secures Two Firsts With US Sprycel And Oxtellar ER Rivals
After announcing several deals that push Apotex into branded product waters, the Canadian player has announced two landmark first generic drug launches in the US.
Henlius Reports Near 10% Revenue Growth In First Half Of 2024
Henlius’ results for the first half of 2024 have shown a continued trend in growing sales of its core biological products on the backdrop of the company’s ongoing privatization by parent company Fosun Pharmaceutical.
Why Is Animal Testing Still With Us?
Despite increased openness by regulators and technological progress, the adoption of alternatives to animal testing remains challenging. The need for data validation by agencies and companies is a big factor.
European Commission Approves Celltrion’s Stelara Biosimilar
The European Commission followed the CHMP’s opinion and fully approved Celltrion’s Stelara biosimilar Steqeyma, making this the fourth approved Stelara rival in the bloc.